<p>Artelo Biosciences Inc. is facing potential delisting from the Nasdaq Stock Market after failing to comply with Listing Rule 5550(b)(1), which requires a minimum stockholders’ equity of $2.5 million. Despite submitting plans to raise additional capital, the company has not met the requirements, leading to a delist determination letter from Nasdaq. Artelo Biosciences intends to appeal the decision, which will temporarily allow its shares to continue trading under the symbol “ARTL” pending the outcome of the hearing. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Artelo Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001640334-25-002210), on November 25, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here</p>

ARTL

<p>Artelo Biosciences Inc. faces potential delisting from Nasdaq for not meeting the minimum stockholders’ equity requirement of $2.5 million. Despite plans to raise capital, the company received a delist determination letter. Artelo Biosciences plans to appeal, allowing shares to trade under “ARTL” pending the hearing outcome.</p>

Nasdaq Issues Delisting Notice to Artelo Biosciences Over Equity Compliance